. 2022 Mar 18;37(12):e94. doi: 10.3346/jkms.2022.37.e94

Table 4. Clinical evaluation results.

Measures	Group	Test results, Median (IQR)					P value	Post-hoc analysis^a
Measures	Group	Unaided	LiNX 3D (premium HA)	Nevara1 (basic HA)	CS50+ (premium PSAP)	Bean (basic PSAP)	P value	Unaided vs. LiNX 3D	Unaided vs. Nevara1	Unaided vs. CS50+	Unaided vs. Bean
Sound-filed audiometry (dB HL)	MHL	40.625 (38.75, 43.75)	31.25 (28.75, 35)	36.625 (32.5, 40)	31.875 (30, 36.25)	30.625 (28.75, 32.5)	< 0.001^***	< 0.001^***	< 0.001^***	0.002^**	< 0.001^***
	MDHL	48.75 (45, 55)	35 (32.4, 40)	45 (41.25, 50)	40.625 (35, 45)	37.5 (33.75, 42.5)	< 0.001^***	< 0.001^***	< 0.001^***	< 0.001^***	< 0.001^***
	MSHL	65 (58.75, 71.25)	45 (41.25, 51.25)	57.5 (53.75, 63.75)	48.75 (42.5, 53.75)	47.5 (45. 55)	< 0.001^***	< 0.001^***	< 0.001^***	< 0.001^***	< 0.001^***
WRS (%)	MHL	92 (92, 96)	96 (92, 96)	92 (92, 96)	92 (84, 96)	96 (96, 100)	0.005^**	0.024^*	< 0.001^***	1.000	0.177
	MDHL	88 (80, 92)	92 (84, 96)	88 (84, 92)	84 (80, 96)	92 (84, 96)	0.001^**	< 0.001^***	< 0.001^***	1.000	0.027^*
	MSHL	60 (24, 68)	88 (52, 92)	76 (40, 84)	68 (52, 88)	80 (52, 92)	< 0.001^***	< 0.001^***	< 0.001^***	0.004^**	< 0.001^***
K-HINT (SNR)	MHL	−0.7 (−1.8, 0.3)	−0.6 (−1.6, 1)	1.4 (−0.3, 2.4)	−0.2 (−1.6, 0.5)	−0.5 (−1.1, 0.3)	0.053	0.002^**	< 0.001^***	< 0.001^***	< 0.001^***
	MDHL	1 (−0.1, 2.8)	0.9 (−0.7, 3.8)	1.4 (−0.1, 2.8)	−0.1 (−1.8, 1.9)	−0.4 (−1.3, 1.3)	0.007^**	> 0.99	> 0.99	0.021^*	0.011^*
	MSHL	4.7 (2.6, 12.1)	5.1 (1.8, 10)	3.3 (2.2, 7.4)	3 (0.7, 10.8)	3.3 (0.8, 6)	0.002^**	0.202	0.002^**	0.179	0.001^**

IQR = inter-quartile range, HA = hearing aid, PSAP = personal sound amplification product, MHL = mild hearing loss, MDHL = moderate hearing loss, MSHL = moderately severe hearing loss, WRS = word recognition score, K-HINT = Korean version of the Hearing In Noise Test.

^aThe comparison result of each device was corrected by the Bonferroni correction method for type I error increase by multiple comparisons.

^*P < 0.05, ^**P < 0.01, ^***P < 0.001.